Re-emerging Antibiotic- A Systematic Review on Colistin
1, 1, 1, 1, 1, 1
- 1Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tirucehngode, Namakkal, Tamil Nadu, INDIA.
CORRESPONDENCE
Shangavi Vellingiri
Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tirucehngode, Namakkal, Tamil Nadu, INDIA.
Volume 15, Issue 3 · pp. 162-166 · 2022 · DOI: 10.5530/ijopp.15.3.31
ABSTRACT
Multidrug-resistant Gram-negative bacteria have become more common in India, and they are linked to lengthier hospital stays. Colistin (Polymyxin E) is a clinically employed antibacterial inactive prodrug of colistin sulfate and colistimethate sodium (CMS). Colistin is an antibiotic used to treat infections caused by MDR Gram-negative bacteria as a last resort. The outer membrane of gram-negative bacteria is bound by the colistin mechanism. Polymyxin E and polymyxin B are commonly utilized in practice. Recent clinical trial methods for the use of colistin with other antibiotics have shown that it can boost antibacterial efficacy, and it will be a “last-line” therapy against MDR gramnegative organisms in the twenty-first century. Clinical uses, dosing considerations, range of efficacy, toxicity level, co-administration with other antibiotics, and prospects are all revealed in the review.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Vellingiri, S., Palanisamy, S. N., Pushpanathan, N., Raju, N., Palanivel, M., & Chinraj, V. D. (2022). Re-emerging Antibiotic- A Systematic Review on Colistin. Indian Journal of Pharmacy Practice, 15(3), 162-166. https://doi.org/10.5530/ijopp.15.3.31
Copyright and licence
© 2022 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0